National Vaccine Panel Recommended to Suspend AstraZeneca Shots Under 55


Ottawa — Sources on Canadian Press to change recommendations by federal vaccination experts to specify that the Oxford-AstraZeneca COVID-19 vaccine should not be used by people under the age of 55 confirmed.

They talked about the background because they weren’t allowed to discuss the move publicly.

A briefing with a doctor from the National Advisory Board on Immunization and Health in Canada is scheduled for this afternoon and will be explained in detail to Canadians.

Health Minister Patty Haidu said Health Canada is very closely monitoring the data following reports of adverse effects in other jurisdictions.

The AstraZeneca vaccine was approved on February 26 for all people over the age of 18, but NACI has since been elderly enough to be convinced of how the vaccine works for people over the age of 65. Was not included in the clinical trial.

Two weeks later, NACI withdrew its advice, citing new real-world evidence from the United Kingdom that the vaccine was highly effective when used in the elderly.

This latest recommendation follows European reports that about 30 patients developed blood clots after vaccination with the AstraZeneca vaccine, most of them young women.

Mia Loveson